Takeda Pharmaceutical Co Ltd
TKDA
Company Profile
Business description
Takeda Pharmaceutical is Japan’s largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company’s five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
Contact
1-1, Nihonbashi-Honcho 2-Chome
Chuo-ku
Tokyo103-8668
JPNT: +81 332782306
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2026
Employees
47,455
Stocks News & Analysis
stocks
Procter & Gamble earnings: Frigid sales and margins don’t suggest cracks in its standing
North America was a notable blemish, down 2% on an organic basis.
stocks
Our view on Santos after production is ramped up
Barossa at 75% capacity and Pikka undergoing commissioning.
stocks
GE Aerospace earnings: No good deed goes unpunished
We’ve raised our fair value estimate of GE Aerospace stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,189.90 | 15.70 | 0.17% |
| CAC 40 | 8,128.32 | 20.57 | -0.25% |
| DAX 40 | 24,882.40 | 25.93 | 0.10% |
| Dow JONES (US) | 49,384.01 | 306.78 | 0.63% |
| FTSE 100 | 10,160.88 | 10.83 | 0.11% |
| HKSE | 26,749.51 | 119.55 | 0.45% |
| NASDAQ | 23,436.02 | 211.20 | 0.91% |
| Nikkei 225 | 53,846.87 | 157.98 | 0.29% |
| NZX 50 Index | 13,448.24 | 108.63 | -0.80% |
| S&P 500 | 6,913.35 | 37.73 | 0.55% |
| S&P/ASX 200 | 8,860.10 | 15.00 | 0.17% |
| SSE Composite Index | 4,136.16 | 13.59 | 0.33% |